Articles from MEDIROM Healthcare Technologies Inc.

Sustained Revenue Growth / Operating Profitability

Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6%

TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (the “Company” or “MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, announces that, on January 14, 2025, all corporate capital registration procedures under Japanese law were completed with respect to the Company’s offering of 2,860,000 common shares represented by American Depositary Shares, generating gross proceeds of approximately $5 million, which offering closed on December 11, 2024. Following the completion of the corporate capital registration procedures, as of the date of this press release, the Company’s registered corporate capital and capital reserve amounts are 365,019,146 yen and 365,019,145 yen, respectively, and the Company has 7,994,451 total outstanding shares of capital stock.

TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare technologies Inc. (NASDAQMRM) (“MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, is pleased to announce that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”) is now providing its remote health monitoring system, REMONY, and charging-free smart tracker device, MOTHER Bracelet®︎, to the Electronics Division of TOPPAN Inc. (Tokyo Stock Exchange: 7911).

Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5%

TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan, including M3, Inc. (TOKYO PRIME: 2413) and Elematec Corporation (TOKYO PRIME: 2715), as well as certain individual investors are also participating. The Series A equity financing round is still ongoing. MEDIROM MOTHER Labs has closed financings with six investors to date and intends to conclude the financing round by December 31, 2024. “We are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre money valuation of 9 billion yen is approximately multiples of MEDIROM’s current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.” said Kouji.

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the closing of its public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000 before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount.

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs Inc. (“Mother Labs”), a subsidiary of MEDIROM, and Yasuhiro Hayami, Chief Business Officer of Mother Labs, invested in Mother Labs’ Series A financing at a pre-money valuation of of JPY9 billion (as of December 1, 2024, approximately USD $59,000,000). Messrs. Homan and Hayami are committed senior executives of Mother Labs and share MEDIROM’s corporate philosophy and vision as well as commitment to future growth potential.

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the pricing of a public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000, before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount. The Offering is expected to close on December 11, 2024, subject to the satisfaction of customary closing conditions.

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc.

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc.

TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09

TOKYO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09

TOKYO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) announced a business alliance with SBC Medical Group Holdings Incorporated (Nasdaq: SBC) a global owner, operator and provider of management services and products to cosmetic treatment centers.

TOKYO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. has formed a capital and business alliance with Elematec Corporation (TOKYO PRIME: 2715), a member of the Toyota Tsusho Corporation group. Under the capital and business alliance agreement, Elematec Corporation has agreed to make a strategic investment in MEDIROM MOTHER Labs’ Series A round at a pre-money valuation of 9 billion yen (approximately US$60,000,000, calculated at an exchange rate of JPY150 to US$1).

TOKYO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (“Medirom” or the “Company”) is pleased to announce that it is capitalizing on its extensive experience operating wellness clinics and healthcare technology to expand into the rehabilitation industry. In doing so, MEDIROM established a wholly-owned subsidiary, MEDIROM Rehab Solutions Inc., which acquired all of the rehabilitation centers of Y’s, Inc. Prior to the acquisition by MEDIROM Rehab Solutions Inc., Y’s, Inc. owned and operated ten cerebral infarction rehabilitation centers in Tokyo and other major cities across Japan.

NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen

TOKYO, July 22, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y’s, Inc., a Japanese corporation, as of July 10, 2024.

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that the Company plans to acquire a majority of Japan Gene Medicine Corporation (the “Target Company”). On June 30, 2024, the Company entered into a share transfer agreement (the "Share Transfer Agreement") to acquire 70.0% of the shares of the Target Company from an individual shareholder. The Company has also entered into a legally binding memorandum of understanding (the "Additional Transfer Memorandum of Understanding"), effective as of June 30, 2024, to obtain an option to acquire the remaining 30.0% of the Target Company’s shares from the seller. The closings of the transactions under the Share Transfer Agreement and Additional Transfer Memorandum of Understanding are each subject to certain conditions. Certain of these closing conditions under the Share Transfer Agreement are summarized below.

Four Nasdaq-listed Japanese Companies Gather to Showcase the Appeal of Japanese Companies to the World

TOKYO, June 25, 2024 (GLOBE NEWSWIRE) --  MEDIROM Healthcare Technologies Inc. (NASDAQMRM) (“Medirom” or the “Company”), a holistic healthcare company based in Japan, announced it filed its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC"), including consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), on June 18, 2024.

Discover the appeal of Japanese companies listed in the U.S.

Total Customers Served: 77,854 – Sales Per Customer: JPY 7,190 – Customer Repeat Ratio: 77.9%

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) --  MEDIROM Healthcare Technologies Inc. (“we”, “our” or “us”) hereby announces that we resolved, at a meeting of our Board of Directors held on March 29, 2024, to enter into a Memorandum of Understanding (the “MOU”) for the purpose of acquiring all of the shares of stock of Japan Gene Medicine Corporation (the “Target Company”) and making it our subsidiary, and commencing the processes and negotiations necessary to enter into the definitive agreement for the transaction. The MOU was executed on April 2, 2024. Under the MOU we and the seller agree to negotiate in good faith for the purpose of entering into the definitive agreement for the acquisition by May 31, 2024, described in more detail below under “2. Outline of Transaction Proposed in the MOU”.

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission (the "SEC") on May 30, 2023. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at http://www.sec.gov as well as through the Company's investor relations website at https://medirom.co.jp/en/ir/.

MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that COZY LLC (“COZY”), a company owned and controlled by Mr. Kouji Eguchi, the CEO and controlling shareholder of the Company, has entered into a stock repurchase plan (the “Plan”) with a U.S. investment bank, under which COZY may purchase up to JPY50 million of the Company’s American Depositary Shares (“ADSs”), each representing one common share of the Company. On January 18, 2023, the Board of Directors of the Company approved the Plan.

MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its preliminary, unaudited financial results for the year ended December 31, 2022, prepared under Japanese GAAP (“JGAAP”). These preliminary financial results and management’s estimates included in this press release are unreviewed, unaudited, and preliminary, are prepared solely in accordance with JGAAP, have not been reviewed or audited under U.S. GAAP, and are based solely on information available to the management of the Company and management’s assumptions and expectations as of the date of this press release, which remain subject to change. Actual results for the year ended December 31, 2022 remain subject to the completion of management’s reviews and reconciliations and/or adjustments under U.S. GAAP, the Company’s other financial closing procedures, and the audit by the independent auditor in accordance with U.S. GAAP, and may differ from these estimated preliminary results due to the completion of the Company’s financial closing procedures, the audit under U.S. GAAP, and other developments that may arise during the audit process. Accordingly, you should not place undue reliance on this preliminary information. See “Important Notice Regarding these Preliminary Financial Results and Management’s Estimates” below.

Total Customers Served: 71,770 – Sales Per Customer: JPY 6,505 – Customer Repeat Ratio: 80.8%